Gritgen is a clinical-stage gene therapy company in Phase III, advancing a next-generation platform and a diversified pipeline. To accelerate global development, we are actively exploring strategic collaborations, including licensing-out, co-development, royalty financing for our programs across different development stages, as well as delivery capsids and promoter technologies. We leverage proprietary AI-driven target discovery and fully integrated platform technologies to enable highly efficient, affordable, and scalable gene therapies for patients worldwide.